adivo is a biotech company generating therapeutic antibodies for companion animals, addressing the medical needs in dogs, with an upside potential for a future in care for other species.
Antibody selection is based on a novel fully synthetic, dog-specific phage display library that allows de-novo identification of antibodies to select a drug candidate with optimal properties.
adivo is a spin-off from MorphoSys AG, a leading European biopharmaceutical company. The team transfers an in-depth expertise in discovery and development of human therapeutic antibodies to the veterinary market.


Pet therapeutic antibody firm adivo announces closure of seed-financing round

German biotech company adivo specializing in generating species-specific therapeutic antibodies for companion animals announces that it received a seed financing from three investors. The adivo team aims to address high medical needs in dogs including cancer and chronic inflammation, with the potential of expanding…

Info & Contact

Kathrin Ladetzki-Baehs
+49 (0) 89 588088-471
Markus Waldhuber
+49 (0) 89 588088-478


adivo GmbH
Am Klopferspitz 19
82152 Martinsried/ Planegg

In portfolio

19. Jul 2018